Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1993 Feb;91(2):602–607. doi: 10.1172/JCI116240

Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment]

S Takei 1, Y K Arora 1, S M Walker 1
PMCID: PMC287991  PMID: 8432865

Abstract

Superantigens are products of bacteria with dual affinity for HLA-DR and the variable region of the beta chain of the T cell receptor, leading to the stimulation of large numbers of T cells. Because there is evidence for the involvement of superantigens in various disease conditions in which intravenous IgG (IVIgG) is used as therapy, the purpose of the present study was to determine if IVIgG contains antibodies inhibitory to T cell stimulation by the superantigens. ELISA and Western assays revealed high concentrations of antibodies in the pooled IgG against eight different staphylococcal toxin (Staph-toxin) superantigens. The IVIgG inhibited in vitro stimulation of human peripheral blood T cells by the Staph-toxins, but did not inhibit responses elicited by phytohemagglutinin or anti-CD3. Inhibition was mediated by Staph-toxin-specific antibodies as shown by affinity adsorption depletion studies. The antibodies functioned by inhibiting the binding and/or presentation of Staph-toxins by DR+ accessory cells. In conclusion, this report is the first to show that normal pooled IgG contains antibodies against a major group of the superantigens, the Staph-toxins, and that the antibodies can inhibit Staph-toxin-elicited T cell activation, suggesting a possible immunoregulatory role for the antibodies in vivo.

Full text

PDF
602

Images in this article

604Image
on p.604

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe J., Kotzin B. L., Jujo K., Melish M. E., Glode M. P., Kohsaka T., Leung D. Y. Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. Proc Natl Acad Sci U S A. 1992 May 1;89(9):4066–4070. doi: 10.1073/pnas.89.9.4066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bergdoll M. S., Huang I. Y., Schantz E. J. Chemistry of the staphylococcal enterotoxins. J Agric Food Chem. 1974 Jan-Feb;22(1):9–13. doi: 10.1021/jf60191a001. [DOI] [PubMed] [Google Scholar]
  3. Carlsson R., Sjögren H. O. Kinetics of IL-2 and interferon-gamma production, expression of IL-2 receptors, and cell proliferation in human mononuclear cells exposed to staphylococcal enterotoxin A. Cell Immunol. 1985 Nov;96(1):175–183. doi: 10.1016/0008-8749(85)90349-1. [DOI] [PubMed] [Google Scholar]
  4. Choi Y., Lafferty J. A., Clements J. R., Todd J. K., Gelfand E. W., Kappler J., Marrack P., Kotzin B. L. Selective expansion of T cells expressing V beta 2 in toxic shock syndrome. J Exp Med. 1990 Sep 1;172(3):981–984. doi: 10.1084/jem.172.3.981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Drake C. G., Kotzin B. L. Superantigens: biology, immunology, and potential role in disease. J Clin Immunol. 1992 May;12(3):149–162. doi: 10.1007/BF00918083. [DOI] [PubMed] [Google Scholar]
  6. Dwyer J. M. Manipulating the immune system with immune globulin. N Engl J Med. 1992 Jan 9;326(2):107–116. doi: 10.1056/NEJM199201093260206. [DOI] [PubMed] [Google Scholar]
  7. Fauci A. S., Schnittman S. M., Poli G., Koenig S., Pantaleo G. NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Ann Intern Med. 1991 Apr 15;114(8):678–693. doi: 10.7326/0003-4819-114-8-678. [DOI] [PubMed] [Google Scholar]
  8. Fleischer B. A conserved mechanism of T lymphocyte stimulation by microbial exotoxins. Microb Pathog. 1989 Aug;7(2):79–83. doi: 10.1016/0882-4010(89)90027-2. [DOI] [PubMed] [Google Scholar]
  9. Fleischer B., Gerardy-Schahn R., Metzroth B., Carrel S., Gerlach D., Köhler W. An evolutionary conserved mechanism of T cell activation by microbial toxins. Evidence for different affinities of T cell receptor-toxin interaction. J Immunol. 1991 Jan 1;146(1):11–17. [PubMed] [Google Scholar]
  10. Fraser J. D. High-affinity binding of staphylococcal enterotoxins A and B to HLA-DR. Nature. 1989 May 18;339(6221):221–223. doi: 10.1038/339221a0. [DOI] [PubMed] [Google Scholar]
  11. Friedman S. M., Posnett D. N., Tumang J. R., Cole B. C., Crow M. K. A potential role for microbial superantigens in the pathogenesis of systemic autoimmune disease. Arthritis Rheum. 1991 Apr;34(4):468–480. doi: 10.1002/art.1780340412. [DOI] [PubMed] [Google Scholar]
  12. Gascoigne N. R., Ames K. T. Direct binding of secreted T-cell receptor beta chain to superantigen associated with class II major histocompatibility complex protein. Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):613–616. doi: 10.1073/pnas.88.2.613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gillis S., Ferm M. M., Ou W., Smith K. A. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978 Jun;120(6):2027–2032. [PubMed] [Google Scholar]
  14. Griggs N. D., Pontzer C. H., Jarpe M. A., Johnson H. M. Mapping of multiple binding domains of the superantigen staphylococcal enterotoxin A for HLA. J Immunol. 1992 Apr 15;148(8):2516–2521. [PubMed] [Google Scholar]
  15. Groux H., Torpier G., Monté D., Mouton Y., Capron A., Ameisen J. C. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med. 1992 Feb 1;175(2):331–340. doi: 10.1084/jem.175.2.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Heyman B., Nose M., Weigle W. O. Carbohydrate chains on IgG2b: a requirement for efficient feedback immunosuppression. J Immunol. 1985 Jun;134(6):4018–4023. [PubMed] [Google Scholar]
  17. Imbach P., Barandun S., Cottier H., Gugler E., Hassig A., Morell A., Wagner H., Heiniger H. Immunomodulation by intravenous immunoglobulin. Am J Pediatr Hematol Oncol. 1990 Summer;12(2):134–140. doi: 10.1097/00043426-199022000-00002. [DOI] [PubMed] [Google Scholar]
  18. Imberti L., Sottini A., Bettinardi A., Puoti M., Primi D. Selective depletion in HIV infection of T cells that bear specific T cell receptor V beta sequences. Science. 1991 Nov 8;254(5033):860–862. doi: 10.1126/science.1948066. [DOI] [PubMed] [Google Scholar]
  19. Józefczyk Z. Specific human antibodies to enterotoxins A, B, and C1 of Staphylococcus: their increased synthesis in staphylococcal infection. J Infect Dis. 1974 Jul;130(1):1–7. doi: 10.1093/infdis/130.1.1. [DOI] [PubMed] [Google Scholar]
  20. Kappler J., Kotzin B., Herron L., Gelfand E. W., Bigler R. D., Boylston A., Carrel S., Posnett D. N., Choi Y., Marrack P. V beta-specific stimulation of human T cells by staphylococcal toxins. Science. 1989 May 19;244(4906):811–813. doi: 10.1126/science.2524876. [DOI] [PubMed] [Google Scholar]
  21. Kunstmann G., Schröder E., Hasbach H., Pulverer G. Immune response to toxic-shock-syndrome toxin-1 (TSST-1) and to staphylococcal enterotoxins A, B and C in Staphylococcus aureus infections. Zentralbl Bakteriol. 1989 Oct;271(4):486–492. doi: 10.1016/s0934-8840(89)80109-4. [DOI] [PubMed] [Google Scholar]
  22. Lee A. C., Robbins R. N., Bergdoll M. S. Isolation of specific and common antibodies to staphylococcal enterotoxins A and E by affinity chromatography. Infect Immun. 1978 Aug;21(2):387–391. doi: 10.1128/iai.21.2.387-391.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. MacDonald H. R., Baschieri S., Lees R. K. Clonal expansion precedes anergy and death of V beta 8+ peripheral T cells responding to staphylococcal enterotoxin B in vivo. Eur J Immunol. 1991 Aug;21(8):1963–1966. doi: 10.1002/eji.1830210827. [DOI] [PubMed] [Google Scholar]
  24. Marrack P., Kappler J. The staphylococcal enterotoxins and their relatives. Science. 1990 May 11;248(4956):705–711. doi: 10.1126/science.2185544. [DOI] [PubMed] [Google Scholar]
  25. Matthes M., Schrezenmeier H., Homfeld J., Fleischer S., Malissen B., Kirchner H., Fleischer B. Clonal analysis of human T cell activation by the Mycoplasma arthritidis mitogen (MAS). Eur J Immunol. 1988 Nov;18(11):1733–1737. doi: 10.1002/eji.1830181112. [DOI] [PubMed] [Google Scholar]
  26. Mollick J. A., Cook R. G., Rich R. R. Class II MHC molecules are specific receptors for staphylococcus enterotoxin A. Science. 1989 May 19;244(4906):817–820. doi: 10.1126/science.2658055. [DOI] [PubMed] [Google Scholar]
  27. Newburger J. W., Takahashi M., Burns J. C., Beiser A. S., Chung K. J., Duffy C. E., Glode M. P., Mason W. H., Reddy V., Sanders S. P. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986 Aug 7;315(6):341–347. doi: 10.1056/NEJM198608073150601. [DOI] [PubMed] [Google Scholar]
  28. Northfelt D. W., Polsky B. Bacteremia in persons with HIV infection. AIDS Clin Rev. 1991:59–79. [PubMed] [Google Scholar]
  29. Notermans S., van Leeuwen W. J., Dufrenne J., Tips P. D. Serum antibodies to enterotoxins produced by Staphylococcus aureus with special reference to enterotoxin F and toxic shock syndrome. J Clin Microbiol. 1983 Nov;18(5):1055–1060. doi: 10.1128/jcm.18.5.1055-1060.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Paliard X., West S. G., Lafferty J. A., Clements J. R., Kappler J. W., Marrack P., Kotzin B. L. Evidence for the effects of a superantigen in rheumatoid arthritis. Science. 1991 Jul 19;253(5017):325–329. doi: 10.1126/science.1857971. [DOI] [PubMed] [Google Scholar]
  31. Pontzer C. H., Russell J. K., Johnson H. M. Structural basis for differential binding of staphylococcal enterotoxin A and toxic shock syndrome toxin 1 to class II major histocompatibility molecules. Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):125–128. doi: 10.1073/pnas.88.1.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Raviglione M. C., Mariuz P., Pablos-Mendez A., Battan R., Ottuso P., Taranta A. High Staphylococcus aureus nasal carriage rate in patients with acquired immunodeficiency syndrome or AIDS-related complex. Am J Infect Control. 1990 Apr;18(2):64–69. doi: 10.1016/0196-6553(90)90083-5. [DOI] [PubMed] [Google Scholar]
  33. Rellahan B. L., Jones L. A., Kruisbeek A. M., Fry A. M., Matis L. A. In vivo induction of anergy in peripheral V beta 8+ T cells by staphylococcal enterotoxin B. J Exp Med. 1990 Oct 1;172(4):1091–1100. doi: 10.1084/jem.172.4.1091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Sasso E. H., Silverman G. J., Mannik M. Human IgA and IgG F(ab')2 that bind to staphylococcal protein A belong to the VHIII subgroup. J Immunol. 1991 Sep 15;147(6):1877–1883. [PubMed] [Google Scholar]
  35. Schröder E., Kunstmann G., Hasbach H., Pulverer G. Prevalence of serum antibodies to toxic-shock-syndrome-toxin-1 and to staphylococcal enterotoxins A, B and C in West-Germany. Zentralbl Bakteriol Mikrobiol Hyg A. 1988 Nov;270(1-2):110–114. doi: 10.1016/s0176-6724(88)80146-9. [DOI] [PubMed] [Google Scholar]
  36. Silverman E. D., Laxer R. M., Greenwald M., Gelfand E., Shore A., Stein L. D., Roifman C. M. Intravenous gamma globulin therapy in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1990 Jul;33(7):1015–1022. doi: 10.1002/art.1780330714. [DOI] [PubMed] [Google Scholar]
  37. Tomai M., Kotb M., Majumdar G., Beachey E. H. Superantigenicity of streptococcal M protein. J Exp Med. 1990 Jul 1;172(1):359–362. doi: 10.1084/jem.172.1.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Vergeront J. M., Stolz S. J., Crass B. A., Nelson D. B., Davis J. P., Bergdoll M. S. Prevalence of serum antibody to staphylococcal enterotoxin F among Wisconsin residents: implications for toxic-shock syndrome. J Infect Dis. 1983 Oct;148(4):692–698. doi: 10.1093/infdis/148.4.692. [DOI] [PubMed] [Google Scholar]
  39. Walker S. M., Shaham B., McCrudy D. K., Wietting H., Arora Y. K., Hanson V., Bernstein B. Prevalence and concentration of IgM rheumatoid factor in polyarticular onset disease as compared to systemic or pauciarticular onset disease in active juvenile rheumatoid arthritis as measured by ELISA. J Rheumatol. 1990 Jul;17(7):936–940. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES